CoTherix Inc About
CoTherix: CoTherix, Inc. is a biopharmaceutical company
focused on licensing, developing and commercializing therapeutic products for
the treatment of cardiopulmonary and other chronic diseases. On December
29, 2004, the U.S. Food and Drug Administration approved CoTherix’s lead product,
Ventavis™ (iloprost) Inhalation Solution, for the treatment of pulmonary
arterial hypertension
(WHO Group I) in patients with NYHA Class III or IV symptoms. Product
Pipeline Data for CoTherix NIH
Data for Trials CoTherix Iloprost --Pulmonary Arterial
Hypertension PAH Pulmonary Hypertension More
on CoTherix
:
Key
Statistics for CoTherix Analyst
Opinion
Basic
Chart for CoTherix
Analysts
Estimates